Abstract: Provided herein are synthetic copolypeptide hydrogel compositions for use as dermal fillers, and methods of treating dermatological conditions using the same.

Abstract: The present invention discloses a cosmetic composition for the treatment of forehead wrinkles, nose fold, crow's feet, cheek density, and cheek hypoechogenic dermal factor.

Abstract: The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

Abstract: Provided herein is a bi-phase composition comprising: (A) a continuous aqueous phase; (B) an oil phase comprising an unstable active agent, and (C) hydrophobic particles adhered on the surface of the oil phase.

Abstract: A skin care composition that contains a combination of a vitamin B3 compound, palmitoyl pentapeptide-4, acetyl tetrapeptide-11, and a dermatologically acceptable carrier. The combination of vitamin B3 compound, palmitoyl pentapeptide-4, and acetyl tetrapeptide-11 increases activation of a cell's Antioxidant Response Element (ARE), (e.g., synergistically) to improve a visible sign of skin aging.

Abstract: An aqueous cosmetic comprising pullulan, a polysaccharide including a uronic acid and a cyclic aldohexose compound as constituent monosaccharides, an amphiphilic substance, and an acrylates/C10-30 alkyl acrylate crosspolymer.

Abstract: A subject-matter of the present invention is a composition in the form of a water-in-oil emulsion, comprising ethylcellulose; at least one first non-volatile oil which is liquid at 25° C. chosen from saturated or unsaturated, linear or branched, C10-C26 fatty alcohols; at least one second non-volatile hydrocarbon-based oil which is liquid at 25° C. chosen from ethers of formula ROR? or carbonates of formula RO(CO)OR?, in which formulae, identical or not, the R and R? groups represent a saturated or unsaturated, branched or unbranched, hydrocarbon-based group comprising at most 16 carbon atoms, preferably a C3-C16 group; and also their mixtures; at least one first non-ionic hydrocarbon-based surfactant.

Abstract: The present invention relates to a cosmetic composition, which is preferably solid, comprising, in a physiologically acceptable medium:—a crosslinked polyurethane elastomer gel comprising a single crosslinked polyurethane elastomer (copolymer) or a mixture of at least two crosslinked polyurethane elastomers (copolymers), wherein said copolymer or said mixture of copolymers is obtained from a prepolymer having at least two hydroxyl groups and from a (poly)isocyanate and at least one solvent, in particular from a carboxylic acid dimer or trimer, from at least one polyol and from a diisocyanate, and—one or more pasty fatty substances chosen from the group consisting of (i) esters of polyol(s) and of a fatty acid dimer diacid, or of an ester thereof, (ii) hydrogenated castor oil esters, (iii) glycerol oligomer esters, in particular digylcerol esters, (iv) and mixtures thereof.

Abstract: The present invention relates to a dry shampoo composition comprising a perfume composition comprising a pro-perfume compound and a dry shampoo active material, a dry shampoo article comprising the same and methods and uses of the same for conferring, improving, enhancing, modifying or prolonging the fragrance intensity of the perfume composition.

Abstract: The instant disclosure relates to hair coloring base compositions containing coconut oil, ready-to-use hair coloring compositions containing coconut oil, and methods for coloring hair. The hair coloring base composition includes: (a) coconut oil; (b) one or more oils other than coconut oil; (c) one or more alkalizing agents; (d) one or more oxidative dye precursors and/or couplers; (e) one or more surfactants; (f) one or more thickening agents; and (g) water. The hair coloring base compositions, the ready-to-use hair coloring compositions, and the methods provide vibrant and durable color to the hair while imparting moisturizing, styling, and anti-frizz properties to the hair; and are particularly useful for curly and very curly hair types.

Abstract: A method of suppressing or eliminating a malodour from a product comprising a bio-sourced ingredient and a container for holding and/or dispensing the ingredient, wherein the bio-sourced ingredient contains ocimene and wherein the method comprises at least one of the steps of preventing reaction between ocimene and the container; physically removing any malodour formed; or treating the product with a malodour-counteracting agent.

Abstract: The invention provides an oil balm cleansing cosmetic composition comprising (A) an oil and (B) an oil gelling agent, wherein component (B) comprises (B1) a polysaccharide fatty acid ester that includes a fatty acid ester of inulin, and (B2) a multichain multi-hydrophilic group-containing compound having a structure in which two N-acylamino acid salt molecules are linked with lysine.

Abstract: Provided is a Saccharomyces cerevisiae strain deposited under Accession No. KCTC 14268BP; a cosmetic composition, a quasi-drug composition, or a food composition, each including any one or more selected from the group consisting of the strain, a culture thereof, and a fermentation product thereof; a method of improving the skin using the strain, the culture thereof, and the fermentation product thereof; and use of the strain, the culture thereof, and the fermentation product thereof, for the skin improvement.

Abstract: The present disclosure relates to implantable constructs and related compositions comprising a plurality of cells producing antigens and/or immune effector molecules.

Abstract: A disinfecting composition includes at least one alcohol and at least one emollient in amount effective to reduce a stinging sensation produced by contacting a wall of a nasal passage with the alcohol. An applicator generally includes an implement to apply a disinfecting composition to a nasal passage of a patient. A method of disinfecting a nasal passage of a patient includes applying a disinfecting composition to the nasal passage of the patient.

Abstract: Provided herein include compositions, methods and systems for delivery of CRISPR/Cas-mediated gene editing systems using lipid nanoparticles (LNP) to trabecular meshwork cells. Methods, compositions and systems for treating glaucoma are also provided herein, which involve reducing the expression of myocilin (MYOC) gene in the trabecular meshwork cells of patients' eyes.

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Abstract: A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

Abstract: The invention pertains to a vaccine comprising non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, for use in boosting an immune response in a poultry animal directed against the poultry pathogen by administering the vaccine mucosally to the poultry animal. The invention also pertains to a vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, as well as a method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof is described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease are also described.

Abstract: The present invention relates to a dry powder composition for inhalation use obtained by spray drying, comprising voriconazole, or a pharmaceutically active salt thereof, in substantially crystalline form, in an amount greater than 50% by weight with respect to the total amount of the powder. Said powder has a respirable fraction (FPF) greater than 50%, an X90 lower than 6 ?m and an MMAD lower than 5 ?m.

Abstract: A device for protecting neurons and reducing inflammation and adhesion formation following surgery is provided. Also provided is a method for protecting neurons and reducing inflammation and adhesion formation following surgery. The device includes a bioabsorbable substrate and a layer of an oxidation inhibitor mimicking the effects of superoxide dismutase and catalase enzymes located on a surface of the substrate. Oxidation inhibitors that may be used include EUK-8, EUK-134, EUK-189, and EUK-207 (a mimetic of superoxide dismutase/catalase), monosodium luminol or phenyl N-t-butylnitrone or an analog with similar anti-oxidant properties. The oxidation inhibitors reduce oxidative stress and trigger the subject's natural anti-oxidant and anti-inflammatory defenses, thereby reducing neuron death, loss of neuron connectivity, inflammation and scarring and restoring excitatory function of neurons.

Abstract: The present invention provides methods of treating airway reflux using an HIV protease inhibitor that is capable of binding to and inhibiting the enzymatic activity of pepsin. Compositions comprising sustained release formulations of HIV protease inhibitors are also provided for oral administration.

Abstract: Disclosed herein are solid formulations of (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof for preparing liquid suspensions. In another aspect, the instant application provides methods of preparation of liquid suspensions and kits of solid formulations comprising Compound A. In another aspect, the instant application provides methods of treating cancer with formulations of Compound A. Additionally, the instant disclosure provides methods of treating pediatric cancer patients by the administration of formulations of Compound A.

Abstract: The present invention relates to a topical pharmaceutical composition in the form of an oil-in-water emulsion comprising an oily phase based on amitriptyline in its basic form and an alkaline aqueous phase. The invention also relates to a method for treating neuropathic pain or erythromelalgia comprising the topical application to the patient of a pharmaceutical composition according to the invention.

Abstract: The present invention is a composition, and a method for making and administering, a pharmaceutical in unit dosage form in which mitochondria-enriched extracellular vesicles are delivered, “as is” or with an optional suitable carrier, after increasing the mitochondria content of the vesicles by generating the vesicles from a human brain endothelial cell line in the presence of one or more suitable promoting agents. Such mitochondria-enriched vesicles are effective to treat tissues needing amelioration of mitochondrial dysfunction or boosting of mitochondrial function. The EVs intrinsically are able to cross the blood-brain barrier and thus are particularly well suited for treating compromised tissues of the brain in situ. as well as other tissues under stress and in need of treatment not limited to neurologic tissues, and are typically administered parenterally.

Abstract: Provided herein are hypoxia/acidic targeting compounds formulated in lipid-containing nanoparticles (liposomes) containing a diagnostic and/or a therapeutic agent. These nanoparticles can penetrate the blood-brain barrier (BBB) and are useful in the treatment ischemic conditions, as well as systemic conditions with hypoxic environments, such as tumors.

Abstract: Disclosed are liposomal pharmaceutical compositions that can deliver two or more protein kinase inhibitors to function in a synergistic mode for the treatment of cancers. The combination of the protein kinase inhibitors encapsulated in the liposome carriers are useful in achieving desired drug retention, a sustained drug release profile for each therapeutic compound and a synergistic therapeutic effect. Methods for preparing these liposomal pharmaceutical compositions and use of them for treatment of cancers are also disclosed.

Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.

Abstract: A powder mixing device, having: a stand; a frame mounted to the stand, the frame being rotatable around a first axis of rotation; and a mixing vessel mounted to the frame, the mixing vessel being rotatable around the first axis of rotation; wherein the mixing vessel comprises at least two components, a first segment and a second segment, wherein the first segment has a work function higher or lower than a work function of the second segment, and a work function of a powder to be mixed is within the work function of the first segment and the second segment.

Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water.

Abstract: The invention relates to a new modified release oral pharmaceutical form comprising 17?-cyanomethyl-17-?-hydrox-yestra-4,9-dien-3-one (dienogest) and 17a?-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention is directed to an oral pharmaceutical dosage form comprising a capsule containing at least two tablets, each tablet containing at least one different pharmaceutically active ingredient

Abstract: This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

Abstract: Provided are delayed sustained-release oral drug dosage forms comprising a Janus kinase (JAK) inhibitor, such as tofacitinib. In other aspects, provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of treatment and/or prevention associated with the oral drug dosage forms described herein.

Abstract: The present invention discloses a sealing fluid comprising an organic acid, an alcohol and optionally water, the organic acid is lactic acid or acetic acid, the alcohol is isopropanol or ethanol, the sealing fluid is a liquid composition for sealing telescopically joined hard capsules with coaxial partly overlapping body parts.

Abstract: A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan. The composition may also include any or all of a hydration promotor, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles having an average diameter between 500 nm and 2000 nm are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

Abstract: Provided herein are pharmaceutical or dietary supplement compositions, kits comprising pharmaceutical or dietary supplement compositions, methods of treating and preventing disease, and methods of making compositions and kits described herein. The pharmaceutical or dietary supplement composition compositions described herein can be administered orally. The pharmaceutical or dietary supplement compositions can be administered by a capsule described herein.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: There is provided a microparticle comprising magnetic nanoparticles within a matrix such as a polymer sphere, wherein the magnetic nanoparticles have an anisotropy constant K in the range 1.0 to 3.0×105 ergs cm?3 and exhibit a hysteresis loop under an alternating magnetic field so as to generate hysteresis heating whilst fixed within the polymer sphere. The alternating magnetic field has a maximum field strength in the range 100 to 400 Oe and a frequency in the range 25 kHz to 500 kHz. The magnetic nanoparticles have an axial ratio of at least 1.1 and are preferably magnetite and substantially crystalline. A method of synthesising such magnetic nanoparticles is also provided.

Abstract: The present disclosure provides technologies relating to stabilization of lipid nanoparticle mRNA compositions (e.g., vaccines).

Abstract: Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.

Abstract: A photosensitizer molecule increases the retention time thereof in a tumor and the enhancement of the therapy for large-volume tumors. AN-BDP is synthesized by means of introducing anthracene into BODIPY-meso, and due to the strong intermolecular ?-? interaction of anthracene, AN-BDP and an amphiphilic block copolymer DSPE-PEG2000 are self-assembled into stable nanoparticles AN-BDP NPs. By means of anthracene, AN-BDP can be excited to a triplet excited state under light irradiation and acts with O2 to generate 1O2. AN-BDP NPs are enriched at the tumor site and retained for about 10 days after tail vein injection. In a mouse tumor model having a conventional volume tumor, AN-BDP NPs can completely inhibit the growth of the tumor by means of one-time tail vein injection and one-time photoirradiation therapy.

Abstract: The present invention refers to a pharmaceutical composition comprising a release-controlled nanocarrier consisting of core-shell nanoparticles which in turn comprises EGF growth factor and bFGF growth factor. This pharmaceutical composition in used in the context of the present invention for preventing radiation-induced damage in cancer patients treated with radiotherapy.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA.

Abstract: An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.